Stay updated on Azacitidine and Pembrolizumab in MDS Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in MDS Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page changes from a 403 Forbidden response to the ClinicalTrials.gov record for the azacitidine and pembrolizumab study, displaying its overview, eligibility criteria, treatment plan, outcomes, investigators, and study documents.SummaryDifference51%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to transition updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden message with minimal navigation, replacing the previously expected study-record content.SummaryDifference19%

Stay in the know with updates to Azacitidine and Pembrolizumab in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.